Role of the TMPRSS2-ERG gene fusion in prostate cancer

Neoplasia

Volumn 10, Issue 2, 2008, Pages 177-188

  Tomlins, Scott A ^a   Laxman, Bharathi ^a   Varambally, Sooryanarayana ^a   Cao, Xuhong ^a   Yu, Jindan ^a   Helgeson, Beth E ^a   Cao, Qi ^a   Prensner, John R ^a   Rubin, Mark A ^b   Shah, Rajal B ^a   Mehra, Rohit ^a   Chinnaiyan, Arul M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR ERG;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION; GENE FUSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; TMPRSS2 ERG GENE; TUMOR GENE;

EID: 39049150843     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07822     Document Type: Article

References (48)

1. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, Shah RB, et al. (2006). TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 66, 3396-3400.
2. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648.
3. Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, et al. (2008). Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 68, 73-80.
4. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene.
5. Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, van de Rijn M, Huntsman DG, Brooks JD, and Pollack JR (2007). A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 20, 467-473.
6. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, et al. (2006). TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66, 8337-8341.
7. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, et al. (2007). TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 31, 882-888.
8. Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, and Panagopoulos I (2006). Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 45, 717-719.
9. Wang J, Cai Y, Ren C, and Ittmann M (2006). Expression of variant TMPRSS2/ ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66, 8347-8351.
10. Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, Jeronimo C, and Teixeira MR (2006). TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 8, 826-832.
11. Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS, Eeles R, Martin FL, Phillips DH, Crundwell M, et al. (2006). Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 26, 2667-2673.
12. Hermans KG, van Marion R, van Dekken H, Jenster G, vanWeerden WM, and Trapman J (2006). TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 66, 10658-10663.
13. Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, Peltola M, Smit F, Verhaegh G, Schalken J, et al. (2006). TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 66, 10242-10246.
14. Yoshimoto M, Joshua AM, Chilton-Macneill S, Bayani J, Selvarajah S, Evans AJ, Zielenska M, and Squire JA (2006). Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 8, 465-469.
15. Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM, et al. (2007). Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 20, 538-544.
16. Nam RK, Sugar L, Wang Z, Yang W, Kitching R, Klotz LH, Venkateswaran V, Narod SA, and Seth A (2007). Expression of TMPRSS2 ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 6, 40-45.
17. Rajput AB, Miller MA, De Luca A, Boyd N, Leung S, Hurtado-Coll A, Fazli L, Jones EC, Palmer JB, Gleave ME, et al. (2007). Frequency of the TMPRSS2: ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 60, 1238-1243.
18. Winnes M, Lissbrant E, Damber JE, and Stenman G (2007). Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep 17, 1033-1036.
19. Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD, Hood L, and Nelson PS (1999). Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 59, 4180-4184.
20. Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R, et al. (2007). Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 9, 200-206.
21. Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J, and Jenster G (2006). Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 66, 5012-5020.
22. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, et al. (2007). Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448, 595-599.
23. Zhang J, Thomas TZ, Kasper S, and Matusik RJ (2000). A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 141, 4698-4710.
24. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, and Sawyers CL (2003). Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223-238.
25. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, et al. (2004). Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64, 2270-2305.
26. Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, Lin DL, and Pienta KJ (2001). VCaP, a cell-based model system of human prostate cancer. In Vivo 15, 163-168.
27. Stegmaier K, Wong JS, Ross KN, Chow KT, Peck D, Wright RD, Lessnick SL, Kung AL, and Golub TR (2007). Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med 4, e122.
28. Rhodes DR, Kalyana-Sundaram S, Tomlins SA, Mahavisno V, Kasper N, Varambally R, Barrette TR, Ghosh D, Varambally S, and Chinnaiyan AM (2007). Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 9, 443-454.
29. Shyamsundar R, Kim YH, Higgins JP, Montgomery K, Jorden M, Sethuraman A, van de Rijn M, Botstein D, Brown PO, and Pollack JR (2005). A DNA microarray survey of gene expression in normal human tissues. Genome Biol 6, R22.
30. Oudes AJ, Campbell DS, Sorensen CM, Walashek LS, True LD, and Liu AY (2006). Transcriptomes of human prostate cells. BMC Genomics 7, 92.
31. Boyd KE, Wells J, Gutman J, Bartley SM, and Farnham PJ (1998). c-Myc target gene specificity is determined by a post-DNA binding mechanism. Proc Natl Acad Sci USA 95, 13887-13892.
32. DeMarzo AM, Nelson WG, Isaacs WB, and Epstein JI (2003). Pathological and molecular aspects of prostate cancer. Lancet 361, 955-964.
33. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, et al. (2007). Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39, 41-51.
34. Dechow TN, Pedranzini L, Leitch A, Leslie K, Gerald WL, Linkov I, and Bromberg JF (2004). Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA 101, 10602-10607.
35. Laufs S, Schumacher J, and Allgayer H (2006). Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 5, 1760-1771.
36. Fingleton B (2006). Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci 11, 479-491.
37. de Launoit Y, Baert JL, Chotteau-Lelievre A, Monte D, Coutte L, Mauen S, Firlej V, Degerny C, and Verreman K (2006). The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis. Biochim Biophys Acta 1766, 79-87.
38. Vassalli JD and Belin D (1987). Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 214, 187-191.
39. Gils A and Declerck PJ (2004). Plasminogen activator inhibitor-1. Curr Med Chem 11, 2323-2334.
40. Vanaja DK, Cheville JC, Iturria SJ, and Young CY (2003). Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 63, 3877-3882.
41. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, and Gerald WL (2004). Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113, 913-923.
42. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, et al. (2004). Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101, 811-816.
43. Wolfgang CD, Essand M, Vincent JJ, Lee B, and Pastan I (2000). TARP: a nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus. Proc Natl Acad Sci USA 97, 9437-9442.
44. Henshall SM, Afar DE, Rasiah KK, Horvath LG, Gish K, Caras I, Ramakrishnan V, Wong M, Jeffry U, Kench JG, et al. (2003). Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene 22, 6005-6012.
45. Tomlins SA, Rubin MA, and Chinnaiyan AM (2006). Integrative biology of prostate cancer progression. Annu Rev Pathol 1, 243-271.
46. Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, Shen MM, and Abate-Shen C (2002). Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 99, 2884-2889.
47. Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK, Humphrey PA, and Milbrandt J (2002). Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 22, 1495-1503.
48. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, and Pandolfi PP (2001). Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27, 222-224.